JMP Securities Starts Incyte (INCY) at Market Outperform
More News related to INCY
- Incyte to Report Second Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on July 31
- Vertos Medical Inc. Completes Series C Financing
- Collegium Pharmaceutical Announces Completion of Series D Financing
- Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
- Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in Phase IIa Rheumatoid Arthritis Study
More News related to New Coverage
- CL King Starts Powerwave (PWAV) at Accumulate
- BMO Starts MAG Silver (MVG) at Outperform
- Morgan Keegan Starts Hanesbrands (HBI) at Outperform
- Wachovia Initiates MDC Partners (MDCA) with an Outperform
- Piper Jaffray Initiates Boston Scientific (BSX) with a Buy
JMP Securities initiates coverage on Incyte (Nasdaq: INCY) with a Market Outperform rating.
Incyte Corporation operates as a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases. [BCS]
Related Categories
New CoverageStocks Mentioned
+0.35Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
